Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14731 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2024. Verfasst von Susan Bodie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pulmatrix Inc., Bedford, Massachusetts, USA. Hauptthemen laut MEDLINE: Dihydroergotamine, Administration, Intravenous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pulmatrix Inc..
Abstract (Originalsprache)
Background
Intravenous dihydroergotamine (DHE) has well‐established efficacy for the acute treatment of migraine, but its use is limited by the need for in‐hospital administration and the nausea/vomiting associated with a high maximum plasma concentration (C max ). Inhalation is an alternative to intravenous dosing. The surface area of the lung allows for rapid absorption of a self‐administered dose.
Objective
This study evaluated the safety, tolerability, and systemic pharmacokinetics (PK) of a dry powder formulation (PUR3100) DHE when delivered via inhalation compared to intravenous delivery. Method s In this double‐blind, double‐dummy Phase 1 study, healthy volunteers ( N = 26) were randomized (1:1:1:1) to one of four groups: orally inhaled placebo plus intravenous DHE 1.0 mg or orally inhaled PUR3100 (0.5, 1.0, or 1.5 mg) plus intravenous placebo. Blood samples were drawn pre‐dose and at time points post‐dose over 48 h. Standard PK and safety parameters were assessed and values for C max and area under plasma concentration time curve (AUC) were used to assess comparative exposures of PUR3100 versus intravenous DHE.
Results
All doses of PUR3100 were associated with a lower incidence of nausea (21% vs. 86%), vomiting (0% vs. 29%), and headache (16% vs. 57%) compared to intravenous DHE. The PK profile of PUR3100 versus intravenous DHE was characterized by a similar mean time to C max (5 vs. 5.5 min), with reduced AUC 0–2h (1120–4320 vs. 6340), and a lower C max (3620–14,400 vs. 45,000). Compared to intravenous DHE 1.0 mg, the highest nominal PUR3100 dose (1.5 mg), which delivers a fine‐particle dose of approximately 0.9 mg to the lungs, had a geometric mean ratio percentage (90% confidence interval [CI]) for C max of 32% [17.2, 59.6] and AUC 0–inf of 93% (62.9, 138.5), the latter of which was not significantly different.
Conclusions
Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and an improved safety profile relative to intravenous DHE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmatrix Inc., Bedford, Massachusetts, USA.
- Veristat, Southborough, Massachusetts, USA.
Förderung
- Pulmatrix Inc.
Zitieren
APA
Bodie, S., Curran, A. K., Gonzalez-Nelson, A. C., Perry, J. M., Manning, D. C., & Wasilewski, M. M. (2024). Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14731
Vancouver
Bodie S, Curran AK, Gonzalez-Nelson AC, Perry JM, Manning DC, Wasilewski MM. Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14731
BibTeX
@article{Bodie2024,
author = {Bodie, Susan and Curran, Aidan K and Gonzalez-Nelson, Aaron C and Perry, Jason M and Manning, Debora C and Wasilewski, Margaret M},
title = {Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14731}
}
EUVIMED